Skip to Content

EpiQuil selected for UNSW Health10x 2026 Accelerator

3 Aug

Written by Helene Klein

EpiQuil receives ethics approval for preclinical pharmacokinetic study

ENGINEERING CONTROL INTO EVERY DOSE

COMPANY

CONTACT

info@epiquil.com

Sydney, Australia

RESEARCH COLLABORATORS

EpiQuil's technologies are investigational. They are not approved by the TGA or any other regulator, and they are not available for supply.

© 2026 EpiQuil Pty Ltd. All rights reserved

ABN 59 692 871 266.